Kala Pharmaceuticals Inc (KALA) Stock Forecast & Price Target
Kala Pharmaceuticals Inc · NASDAQ
$0.81+0.02 (+2.30%)
15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Kala Pharmaceuticals Inc, 2 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $30.00 to $35.00, so the covering firms are broadly aligned. The average target of $32.67 sits 3915% above the current $0.81. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.32 next quarter toward $-0.53 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy267%
Hold133%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Kala Pharmaceuticals Inc.
As of Aug, 2 of 3 firms rate KALA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
KALA EPS & revenue forecast
EPS · THIS QUARTER
$-0.32
Range $-0.32 – $-0.32 · 1 analysts · -82% YoY
Next period, 1 analysts expect Kala Pharmaceuticals Inc to earn $-0.32 a share (range $-0.32 – $-0.32), versus $-1.74 a year earlier. , growing to $-0.53 the year after.
REVENUE · THIS QUARTER
—
Range — – — · 1 analysts
Revenue is expected to reach — (range — – —)., rising to $0 next year.
Top analysts covering Kala Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KALA.
#1
Andreas Argyrides
Oppenheimer · Rank #275
Buy
$33.00+3955.5% to target
Overall win rate
44%
+ Follow
#2
Yi Chen
HC Wainwright & Co. · Rank #276
Hold
No targeton KALA
Overall win rate
33%
+ Follow
#3
Aydin Huseynov
Ladenburg Thalmann · Rank #422
Buy
$600.00+73637.2% to target
Overall win rate
34%
+ Follow
#4
Graig Suvannavejh
Mizuho
Hold
$75.00+9117.2% to target
Coverage
—
+ Follow
KALA stock forecast FAQ
What is KALA's average 12-month price target?+
The 2 analysts with a live target average $32.67 for Kala Pharmaceuticals Inc over the next 12 months, ranging from a $35.00 high to a $30.00 low.
Is KALA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 2 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for KALA?+
The Street-high target is $35.00, and the Street-low is $30.00 (Mizuho). The average of all 2 active targets is $32.67.
How many Wall Street analysts cover KALA?+
3 analysts have an active rating on Kala Pharmaceuticals Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering KALA?+
Among analysts who currently cover KALA, Andreas Argyrides of Oppenheimer has the strongest overall Quantellect track record (Rank #275). Their current call is Buy with a $33.00 target.
What is Kala Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.32 per share (range $-0.32 – $-0.32) across 1 analysts, rising to $-0.53 the following year.
How much revenue is Kala Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is — (range — – —), growing to $0 next year.
Have analysts been upgrading or downgrading KALA lately?+
As of Aug, 2 of 3 firms rate KALA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KALA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
